| Literature DB >> 30618513 |
Hyun-Bin Kwak1, Jin Park1,2, Han-Uk Kim1,2, Kyung-Hwa Nam3, Seok-Kweon Yun1,2.
Abstract
BACKGROUND: Cutaneous carcinosarcoma is a rare biphasic tumor comprising malignant epithelial and heterologous mesenchymal elements. Data on the clinical and histopathologic characteristics of this tumor in Asian populations are not available. The purpose of this study was to investigate the clinicopathologic and immunohistochemical features of cutaneous carcinosarcoma in the Korean population.Entities:
Keywords: Cutaneous Carcinosarcoma; Korean Population; Pathology
Mesh:
Substances:
Year: 2018 PMID: 30618513 PMCID: PMC6318441 DOI: 10.3346/jkms.2019.34.e5
Source DB: PubMed Journal: J Korean Med Sci ISSN: 1011-8934 Impact factor: 5.354
Clinical characteristics in 11 patients with cutaneous carcinosarcoma
| Case, No. | Age/gendera | Location | Duration, mon | Size, mm | Ulcer | Clinical Dx | Metastasis | Tx | F/U, mon | Rec |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 77M | Penile tip | ND | 7 | + | SCC | Inguinal LN | WE, LAT | 60 | − |
| 2 | 96W | Scalp | 12 | 12 | − | SCC | - | WE | 15 | − |
| 3 | 87W | Cheek | 24 | 14 | + | BCC | - | WE | 16 | − |
| 4 | 43M | Cheek | 1 | 10 | + | SCC | - | WE | 40 | − |
| 5 | 74W | Neck | 6 | 50 | + | KA | Cervical LN | WE, LAT | 21 | + |
| 6 | 96M | Auricle | ND | 10 | − | BCC | - | WE | 2 | − |
| 7 | 68W | Calf | 18 | 20 | + | SCC | - | WE | 12 | − |
| 8 | 45M | Cheek | 4 | 10 | + | BCC | - | MMS | 34 | − |
| 9 | 63M | Thigh | 18 | 20 | − | SCC | Inguinal LN | WE, LAT | 24 | + |
| 10 | 79M | Cheek | 6 | 7 | + | SCC | - | WE | 7 | − |
| 11 | 58M | Scalp | 12 | 15 | + | SCC | - | WE | 18 | − |
Dx = diagnosis, Tx = treatment, F/U = follow-up, Rec = recurrence, ND = not described, SCC = squamous cell carcinoma, LN = lymph node, WE = wide excision, LAT = lymphadenectomy, BCC = basal cell carcinoma, KA = keratoacanthoma, MMS = Mohs micrographic surgery.
aM, men and W, women.
Fig. 1An ulcerated nodule on the right cheek in an 87-year-old woman.
Histopathologic and immunohistochemical characteristics in 11 cutaneous carcinosarcoma cases
| Case, No. | Malignant epithelial dysplastic cells (SCC or BCC) | Malignant dysplastic spindle cells | Transition between cell components | Immunohistochemical markers, carcinomatous area/sarcomatous area | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cytokeratin, AE1/AE3 | EMA | p53 protein | p63 protein | Vimentin | Desmin | S-100 | ||||
| 1 | +, SCC | + | + | +/+ | +/+ | +/− | +/− | −/+ | −/− | −/− |
| 2 | +, SCC | + | − | +/− | +/− | +/− | +/− | −/+ | −/− | −/− |
| 3 | +, SCC | + | + | +/+ | +/− | −/+ | +/− | −/+ | −/− | −/− |
| 4 | +, SCC | + | + | +/+ | +/− | +/− | +/− | −/+ | −/− | −/− |
| 5 | +, SCC | + | + | +/+ | +/+ | −/+ | +/− | +/− | −/− | −/+ |
| 6 | +, SCC | + | + | +/− | +/− | −/+ | +/− | −/+ | −/− | −/− |
| 7 | +, SCC | + | − | +/+ | +/− | +/+ | +/− | −/+ | −/− | −/− |
| 8 | +, SCC | + | + | +/− | +/− | −/+ | −/+ | −/+ | −/− | −/− |
| 9 | +, SCC | + | − | +/+ | +/+ | +/+ | −/− | −/+ | −/− | −/− |
| 10 | +, BCC | + | + | +/− | +/− | +/− | +/− | −/+ | −/− | −/− |
| 11 | +, SCC | + | + | +/+ | +/− | −/− | +/− | −/+ | −/− | −/− |
SCC = squamous cell carcinoma, BCC = basal cell carcinoma, EMA = epithelial membrane antigen.
Fig. 2Histopathologic findings of cutaneous carcinosarcoma. (A) The transition zone between carcinomatous and sarcomatous areas (H & E, × 100). (B) Clumped chromatins and marked mitotic activities in sarcomatous area (H & E, × 400).
Overall immunohistochemical summary of cutaneous carcinosarcomas
| Antibody | No. of cases (%) | |
|---|---|---|
| Epithelial cells positive | Spindle cells positive | |
| Cytokeratin (AE1/AE3) | 11 (100) | 7 (63.6) |
| EMA | 11 (100) | 3 (27.3) |
| p53 protein | 6 (54.5) | 6 (54.5) |
| P63 protein | 9 (81.8) | 1 (9.1) |
| Vimentin | 1 (9.1) | 10 (90.9) |
| Desmin | 0 (0) | 0 (0) |
| S-100 | 0 (0) | 1 (9.1) |
EMA = epithelial membrane antigen.
Fig. 3Immunohistochemical findings of cutaneous carcinosarcoma (A, B) Cytokeratin AE1/AE3 expression in the squamous and spindle cells (immunoperoxidase, × 400). (C, D) Strong positive nuclear p53 protein expression, similar in the squamous and sarcomatous cells (immunoperoxidase, × 400). (E, F) Vimentin expression in the squamous and spindle cells (immunoperoxidase, × 400).